Quest Diagnostics Is Worthy Of More Attention

After nearly two years of flat to falling revenue, it's just plain difficult for Quest Diagnostics (NYSE: DGX  ) to get any positive attention, especially with the black cloud of reimbursement uncertainty hanging over its industry. To end the year, shares of BRCA test pioneers Myriad Genetics (NASDAQ: MYGN  ) were clobbered after a price readjustment from the Centers of Medicare and Medicade Services. The market has let shares of Quest fall to their lowest level in over two years. This could be an opportunity to pick up a great company at a very attractive price.

Read the full article only at The Motley Fool, here.